Covid treatment reduced deaths by 70%

In its latest Phase 2 trial at three major Israeli hospitals, MesenCure from Israel’s Bonus BioGroup (see here previously) reduced Covid-19 deaths to 6.7% compared to 23.3% of the control group. It is now aiming for emergency use authorization in US, EU, and Israel.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published.